DNA polymerase κ (pol κ) inhibitors constitute a distinctive class of chemical compounds meticulously crafted to intricately interfere with the activity of the DNA polymerase κ enzyme. DNA polymerase κ, categorized within the Y-family of DNA polymerases, holds a specialized role in processes of DNA replication and repair, particularly when confronted with damaged DNA templates. The inhibitors within this class are typified by their profound capability to intricately bind to the catalytic active site of pol κ. By forming this binding interaction, they perturb the enzyme's fundamental function of orchestrating the addition of nucleotides to the elongating DNA strand during replication and repair processes. This binding-induced obstruction causes a significant disruption in the natural sequence of nucleotide incorporation, leading to a consequential stall in the progression of replication or repair machinery. This impact becomes particularly pronounced when cells are challenged by DNA damage, as pol κ is a pivotal component of the translesion synthesis (TLS) pathway.
The TLS pathway functions as a molecular workaround, enabling cells to maneuver past various types of DNA lesions and subsequently resume DNA replication. However, this mode of replication is error-prone and often results in the introduction of mutations, compromising genomic integrity. DNA pol κ inhibitors stand as strategic tools with the potential to finely regulate DNA repair accuracy. By preventing the erroneous insertion of nucleotides opposite damaged DNA bases, these inhibitors possess the capacity to influence the overall fidelity of DNA repair processes. Constructing such inhibitors necessitates an intricate comprehension of the three-dimensional structural intricacies of DNA polymerase κ's active site. Consequently, their development requires a meticulous integration of structural insights and chemical design principles, facilitating the creation of compounds that possess the precision to selectively target and manipulate this specific DNA polymerase.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a cyclin-dependent kinase (CDK) inhibitor that disrupts cell cycle progression and affects DNA repair mechanisms. | ||||||
ETP-46464 | 1345675-02-6 | sc-497432 | 10 mg | $550.00 | ||
ETP-46464 inhibits pol κ by binding to its active site, preventing nucleotide incorporation during DNA synthesis. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
VE-821 is an ATR kinase inhibitor that impairs the ATR-CHK1 pathway, affecting the ability of cells to repair DNA damage. | ||||||
G007-LK | 1380672-07-0 | sc-507467 | 1 mg | $48.00 | ||
G007-LK is an inhibitor of pol κ that sensitizes cancer cells to DNA damage by suppressing translesion synthesis. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
BI-2536 targets multiple kinases including CDK1, leading to cell cycle arrest and interfering with DNA damage repair. | ||||||
A-196 | 1982372-88-2 | sc-507414 | 1 mg | $72.00 | ||
A-196 inhibits pol κ by occupying its active site and preventing proper nucleotide insertion during DNA synthesis. | ||||||